Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma.

被引：0
|
作者：
Vandenberg, Cassandra J. [1 ]
Ho, Gwo-Yaw [1 ]
Nesic, Ksenija [1 ]
Swisher, Elizabeth M. [2 ]
Grimmond, Sean M. [3 ]
Wakefield, Matthew J. [1 ]
Barker, Holly E. [1 ]
Bowtell, David D. [4 ]
Scott, Clare L. [1 ]
机构：
[1] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ Melbourne, Parkville, Vic, Australia
[4] Peter MacCallum Canc Inst, Melbourne, Vic, Australia
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ovarian carcinosarcoma share similar molecular profile as ovarian serous carcinoma but not endometrial carcinosarcoma.
    Mahdi, Haider
    Xiu, Joanne
    Reddy, Sandeep K.
    Debernardo, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer
    Trudel, Dominique
    Avarvarei, Luminita-Mihaela
    Orain, Michele
    Turcotte, Stephane
    Plante, Marie
    Gregoire, Jean
    Kappelhoff, Reinhild
    Labbe, David P.
    Bachvarov, Dimcho
    Tetu, Bernard
    Overall, Christopher M.
    Bairati, Isabelle
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (06)
  • [3] Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
    Hollis, Robert L.
    Croy, Ian
    Churchman, Michael
    Bartos, Clare
    Rye, Tzyvia
    Gourley, Charlie
    Herrington, C. Simon
    BRITISH JOURNAL OF CANCER, 2022, 127 (06) : 1034 - 1042
  • [4] Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
    Robert L. Hollis
    Ian Croy
    Michael Churchman
    Clare Bartos
    Tzyvia Rye
    Charlie Gourley
    C. Simon Herrington
    British Journal of Cancer, 2022, 127 : 1034 - 1042
  • [5] SHOULD AROMATASE INHIBITORS BE USED AS MAINTENANCE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?
    Heinzelmann-Schwarz, V.
    Knipprath-Meszaros, A. M.
    Francis, J.
    Stadlmann, S.
    Vigo, F.
    Schoetzau, A.
    Singer, G.
    Vetter, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 307 - 307
  • [6] SHOULD AROMATASE INHIBITORS BE USED AS MAINTENANCE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?
    Heinzelmann-Schwarz, V.
    Knipprath-Meszaros, A. M.
    Francis, J.
    Stadlmann, S.
    Vigo, F.
    Schoetzau, A.
    Singer, G.
    Vetter, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1547 - 1547
  • [7] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
  • [8] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Robert D. Morgan
    Andrew R. Clamp
    D. Gareth R. Evans
    Richard J. Edmondson
    Gordon C. Jayson
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 647 - 658
  • [9] PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
    Dickson, Kristie-Ann
    Xie, Tao
    Evenhuis, Christian
    Ma, Yue
    Marsh, Deborah J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [10] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
12345